Relationship between Positional Obstructive Sleep Apnea and Excessive Daytime Sleepiness in Patients with Atrial Fibrillation
Abstract
Purpose: Obstructive sleep apnea (OSA) is highly prevalent in patients with atrial fibrillation (AF). Prior studies suggest that excessive daytime sleepiness (EDS), a common symptom of OSA, is less pronounced in patients with AF. This study focused on a subtype of OSA, positional OSA (POSA), and examined its association with EDS overall and separately in patients with and without AF.
Methods: This study included 222 OSA patients with and without AF history who underwent in-lab polysomnography. POSA was defined using three criteria: conventional POSA (cPOSA; supine/non-supine apnea-hypopnea index [AHI] ratio ≥ 2), intermediately conservative POSA (iPOSA; supine/non-supine AHI ratio ≥ 3), and exclusive POSA (ePOSA; supine/non-supine AHI ratio ≥ 2 and non-supine AHI < 5 events/h). EDS was determined by an Epworth Sleepiness Scale score ≥ 11. Logistic regression was performed to assess the associations.
Results: Overall, 55.4% of patients had cPOSA, and 43.6% reported EDS. Analysis of the entire cohort showed that patients with cPOSA (adjusted odds ratio [aOR]: 0.51, 95% confidence interval [CI]: 0.26-0.98) or iPOSA (aOR: 0.37, 95% CI: 0.18-0.74) had lower odds of EDS than their non-POSA counterparts. Among patients with AF, cPOSA was associated with lower odds of EDS (aOR: 0.32, 95% CI: 0.11-0.90). Among patients without AF, iPOSA was associated with lower odds of EDS (aOR: 0.28, 95% CI: 0.10-0.75).
Conclusion: The association between POSA and EDS varied by POSA definitions and…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 222 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.